You’re Taking a GLP-1 for Diabetes. Do You Still Need Metformin?

If you have type 2 diabetes, you’ve probably already been prescribed metformin, a common first-line treatment for the condition. But GLP-1 medications, like semaglutide (Ozempic) and tirzepatide (Mounjaro), are also powerful treatments.
If you’re taking a GLP-1 drug for the first time, you might wonder whether or not it makes sense to continue taking metformin. In fact, these two diabetes medications work very differently even while providing similar benefits. Experts say they work better when taken together. Here’s what you need to know.
Diabetes 101: What Is Metformin?
Next up video playing in 10 seconds
Metformin vs. GLP-1s: How Do They Work?
Metformin is a pill that patients take once or several times per day. GLP-1 medications are generally taken once a week via injection or with a daily pill.
“Metformin and GLP-1s (like Ozempic) are often prescribed together to manage blood sugar levels for people with type 2 diabetes,” explains Vanessa King RDN, CDCES, a spokesperson for the Academy of Nutrition and Dietetics, “because they are different types of medicine that work in synergistic and complementary ways.”
Metformin works mostly by telling your liver to produce less sugar, says King.
“Ozempic and Mounjaro, on the other hand, work by imitating gut hormones that increase your body’s insulin production when you’re eating, slow down how quickly food moves through the digestive tract, and increase satiety and fullness when you’re eating,” adds King. “GLP-1s reduce liver glucose production, too.”
While many of the benefits do overlap, each class of drugs offers different benefits.
Benefits of Metformin
Long considered the “first line of defense” in treating type 2 diabetes, metformin works primarily by suppressing how much glucose (sugar) the liver produces. It can also reduce your appetite, reduce how much sugar is absorbed from the carbohydrates you eat, and slow down the digestion of your meal. All these effects can help with a small amount of weight loss.
“There are so many benefits of metformin. Metformin actually increases your body’s natural GLP-1 production,” explains Lori Wenz, a nurse practitioner who’s been caring for people with type 2 diabetes and obesity for over 10 years at Western Colorado Weight Care in Grand Junction.
But Wenz says researchers are still learning about less-obvious benefits of metformin.
“In research, we also see positive changes in the gut microbiome in people taking metformin,” says Wenz. “We know metformin changes how you absorb macronutrients, particularly carbohydrates, but possibly fats and proteins, too.”
“Other benefits of metformin include that it is safe,” adds King. “And it doesn’t cause weight gain, is highly effective when taken consistently, doesn’t cause hypoglycemia, and it’s relatively affordable.”
While the impact of metformin is significantly more subtle and gradual than that of GLP-1s, it’s still beneficial for almost anyone with diabetes, regardless of other medications.
Benefits of GLP-1s
“GLP-1s like Ozempic have cardiovascular and kidney benefits as well,” explains King. “Research shows it can protect patients with heart disease, heart failure, or chronic kidney disease. But it can also reduce your risk of these conditions if you’re high-risk, including people with diabetes.”
GLP-1s and Metformin Are Most Beneficial When Combined
“Diabetes is a complex health condition,” explains King. “If your A1C is more than 1.5 percent above your target, a combination medication therapy is now the most common strategy per the standards of the American Diabetes Association.”
“Combination medication therapy” means taking more than one diabetes drug at once. Even if you are meeting your blood sugar goals with metformin, your clinician may recommend adding a GLP-1 drug for its other health benefits.
“We have data from past trials that tirzepatide with metformin show greater weight reduction than tirzepatide alone,” explains Wenz on the benefits of Mounjaro. “Some people think you don’t need anything else, or that metformin isn’t as effective, but we know these medications are most effective when you take them together.”
Wenz encourages her patients to take both — if they can access and tolerate both.
“Patients definitely get an additive benefit when taking metformin and Ozempic in combination,” says King.
GLP-1 and Metformin Side Effects
“Both medications have potential digestive side effects and this can be one concern with taking them together,” says King.
“We work on a case-by-case basis to reduce the gastrointestinal side effects,” says King. “In some cases, patients do discontinue taking either medication. Thankfully, there are so many different options for diabetes medications.”
With both drugs, the most common side effects tend to subside after days, weeks, or months, as the body becomes accustomed to the new medication or a higher dosage.
Access and Affordability
It may be ideal to take both these medications — if you can access them.
“There is so much buzz around Ozempic and Mounjaro related to weight loss, but these drugs are cost-prohibitive for many people,” says King. “Many patients appreciate the low cost of metformin.”
GLP-1 medications can be expensive, difficult to get insurance coverage for, and may be difficult to find because of ongoing shortages. By contrast, metformin is very affordable and easy to get insurance coverage for, too. Some insurance companies may actually require you to take metformin before you’re eligible for a GLP-1.
The Takeaway
- Combining metformin with GLP-1 medications often provides greater benefits in managing type 2 diabetes than taking either medication alone.
- Both GLP-1 and metformin have potential side effects, particularly gastrointestinal issues, which patients should discuss with their healthcare provider if they persist or worsen.
- Access to GLP-1 medications can be challenging due to factors like cost, insurance coverage, and shortages, whereas metformin is generally more affordable and easier to obtain.
Resources We Trust
- Mayo Clinic: The Best Injection Sites for Mounjaro
- Harvard Health: Is Metformin a Wonder Drug?
- American Diabetes Association: Medications for Type 2 Diabetes
- Obesity Action Coalition: Lifestyle Habits to Treat Obesity
- Centers for Disease Control and Prevention: About Insulin Resistance

Sandy Bassin, MD
Medical Reviewer
Sandy Bassin, MD, is an endocrinology fellow at Mount Sinai in New York City. She is passionate about incorporating lifestyle medicine and plant-based nutrition into endocrinology, particularly for diabetes and obesity management.
She trained at the Geisel School of Medicine at Dartmouth, where she taught culinary medicine classes to patients and medical trainees. She continued her training at the Robert Wood Johnson Medical School.
Dr. Bassin has published reviews of nutrition education in medical training and physical activity in type 2 diabetes in Nutrition Reviews, Endocrine Practice, and the American Journal of Lifestyle Medicine. She has been featured on the Physician to Physician Plant-Based Nutrition podcast and given many presentations on lifestyle interventions in endocrine disorders.
She stays active through yoga and gardening, and loves to cook and be outdoors.

Ginger Vieira
Author
Ginger Vieira has lived with type 1 diabetes and celiac disease since 1999, and fibromyalgia since 2014. She is the author of Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, Emotional Eating with Diabetes, and Your Diabetes Science Experiment.
Ginger is a freelance writer and editor with a bachelor's degree in professional writing, and a background in cognitive coaching, video blogging, record-setting competitive powerlifting, personal training, Ashtanga yoga, and motivational speaking.
She lives in Vermont with a handsome husband, two daughters, and a loyal dog named Pedro.
- Daly T et al. Long-term metformin use for Alzheimer's disease prevention? Alzheimer's & Dementia. April 12, 2025.
- Gillani SW et al. Effect of Metformin on Lipid Profiles of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Journal of Pharmacy & Bioallied Sciences. December 16, 2020.
- Wong HJ et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care. February 1, 2025.
- Collins L et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. February 29, 2024.
- Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine. July 11, 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. December 14, 2023.
- Corcoran C et al. Metformin. StatPearls. August 17, 2023.